[18F]Fluoro-azomycin-2 ´-deoxy-β-d-ribofuranoside — A new imaging agent for tumor hypoxia in comparison with [18F]FAZA

Radiolabeled 2-nitroimidazoles (azomycins) are a prominent class of biomarkers for PET imaging of hypoxia. [18F]Fluoro-azomycin- α-arabinoside ([18F]FAZA) – already in clinical use – may be seen as α-configuration nucleoside, but enters cells only via diffusion and is not transported by cellular nucleoside transporters. To enhance image contrast in comparison to [18F]FAZA our objective was to 18F-radiolabel an azomycin- 2´-deoxyriboside with β-configuration ([18F]FAZDR, [18F]-β-8) to mimic nucleosides more closely and comparatively evaluate it versus [18F]FAZA.

Source: Nuclear Medicine and Biology - August 8, 2016 Category: Nuclear Medicine Authors: Anna Schweifer, Florian Maier, Walter Ehrlichmann, Denis Lamparter, Manfred Kneilling, Bernd J. Pichler, Friedrich Hammerschmidt, Gerald Reischl Source Type: research